Capital is rotating toward niche AI infrastructure plays and specialized healthcare assets in the second half of 2026, driven by a search for yields outside mainstream tech, according to people familiar with the matter.

iShares Prime Money Market (PMMF.US)

The money market ETF has recorded stable intraday volume this year, targeting high current income. In August 2026, the fund declared a dividend of USD 0.0706 per share, as management navigates liquidity constraints in the current rate environment.

Creative Medical Technology (CELZ.US)

Shares of the biotech firm have seen double-digit volatility in recent months. The company secured a US patent for its exosome-based type 1 diabetes immunotherapy in August 2026. It is targeting broader platform validation following its osteoarthritis program, which achieved a 93% patient response rate.

Knorex (KNRX.US)

The B2B advertising firm has faced downward pressure due to compliance headwinds. Knorex received a non-compliance notice from the NYSE in May 2026 after failing to file its 2025 annual report. Still, recent AI upgrades to its XPO platform lowered average cost per action by 45% in live campaigns.

Tradr 2X Long NVTS Daily (NVTX.US)

The leveraged ETF rebounded recently, tracking momentum in its underlying asset. The underlying chipmaker reported Q1 2026 revenue of USD 8.6 million, an 18% sequential increase. The company is targeting AI data center markets, pushing non-GAAP gross margins up to 39.0%.

NOMAD Power Solutions (NMAD.US)

The company, formerly LIXTE Biotechnology, pulled back structurally following its pivot to AI energy infrastructure. During the second quarter of 2026, the firm executed a key acquisition and name change, according to executives, while signaling plans to bring on energy-sector veterans to bolster its board.

Advance Auto Parts (AAP.US)

The auto parts retailer has underperformed the broader sector year-to-date. In Q1 2026, the company posted flat net sales of USD 2.6 billion, though gross margins ticked up to 45.1%. Management reaffirmed its 2026 full-year guidance, projecting net sales between USD 8.485 billion and USD 8.575 billion.

Alps Group (ALPS.US)

The healthcare platform's stock has been weighed down by margin compression. Alps Group generated USD 4.86 million in FY2026 revenue, up 44% year-over-year, but gross margins narrowed to 32% due to profit-sharing in its aesthetic services unit. The firm launched an organoid program for personalized cancer care in June.

MV Oil Trust (MVO.US)

The statutory trust trended lower amid expectations of its impending liquidation. The entity posted an income of USD 11.31 million in 2025, a 39.13% decline. According to filings, the trust is set to wind down and cancel units around June 30, 2026.

GMO U.S. Quality ETF (QLTY.US)

The active ETF posted moderate year-to-date gains, buoyed by its underlying quality equity portfolio. In July 2026, management flagged Nvidia as a primary market opportunity, signaling a continued reliance on high-margin technology components within the fund.

Broader market data suggests these microcap tech and specialized yield vehicles are increasingly absorbing risk capital. Analysts project volatility in this specific cohort could widen ahead of the next earnings cycle.

This article does not constitute investment advice.